Comparative analysis of the etanercept efficacy in children with juvenile idiopathic arthritis under the age of 4 years and children of older age groups using the propensity score matching method

References

• Minden K, Niewerth M, Zink A, Seipelt E, Foeldvari I, Girschick H, et al. Long-term outcome of patients with jia treated with etanercept, results of the biologic register jumbo. Rheumatol (United Kingdom). 2012;51(8):1407–15.
   PubMed Web of Science ®Google Scholar
• Horneff G, De Bock FD, Foeldvari I, Girschick HJ, Michels H, Moebius D, et al. Safety and efficacy of combination of Etanercept and methotrexate compared to treatment with Etanercept only in patients with juvenile idiopathic arthritis (JIA): Preliminary data from the German JIA registry. Ann Rheum Dis. 2009;68(4):519–25.
   PubMed Web of Science ®Google Scholar
• Anink J, Prince FHM, Dijkstra M, Otten MH, Twilt M, ten Cate R, et al. Long-term quality of life and functional outcome of patients with juvenile idiopathic arthritis in the biologic era: a longitudinal follow-up study in the Dutch Arthritis and Biologicals in Children Register. Rheumatology (Oxford). 2015;54(11):1964–9.
   PubMed Web of Science ®Google Scholar
• Verazza S, Davì S, Consolaro A, Bovis F, Insalaco A, Magni-Manzoni S, et al. Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. Pediatr Rheumatol. 2016;14(1):11.
   PubMedGoogle Scholar
• Kearsley-Fleet L, Davies R, Lunt M, Southwood TR, Hyrich KL. Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatology 2016;55:840–7.
   PubMed Web of Science ®Google Scholar
• Geikowski T, Becker I, Horneff G. Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis. Rheumatol (United Kingdom). 2014;53(7):1245–9.
   PubMed Web of Science ®Google Scholar
• Solari N, Palmisani E, Consolaro A, Pistorio A, Viola S, Buoncompagni A, et al. Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. J Rheumatol. 2013;40(2):192–200.
   PubMed Web of Science ®Google Scholar
• Otten MH, Prince FHM, Armbrust W, ten Cate R, Hoppenreijs EPAH, Twilt M, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA 2011;306.
   PubMed Web of Science ®Google Scholar
• Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum.2003;48(4):1093–101.
   PubMed Web of Science ®Google Scholar
• Alexeeva EI, Namazova-Baranova LS, Bzarova TM, Valieva SI, Denisova RV, Sleptsova TV, et al. Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children’s Health. Pediatr Rheumatol Online J. 2017;15(1):51. doi: 10.1186/s12969-017-0178-9.
   PubMedGoogle Scholar
• Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63(4):465–82.
   PubMed Web of Science ®Google Scholar
• Giménez-Roca C, Iglesias E, Torrente-Segarra V, Bou R, Sánchez-Manubens J, Calzada-Hernández J, et al. Efficacy and safety of TNF-alpha antagonists in children with juvenile idiopathic arthritis who started treatment under 4 years of age. Rheumatol Int. 2015;35(2):323–6.
   PubMed Web of Science ®Google Scholar
• Bracaglia C, Buonuomo PS, Tozzi AE, Pardeo M, Nicolai R, Campana A, et al. Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age. J Rheumatol. 2012;39(6):1287–90.
   PubMed Web of Science ®Google Scholar
• Windschall D, Müller T, Becker I, Horneff G. Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 2 years. Rheumatol Int. 2015;35(4):613–8.
   PubMed Web of Science ®Google Scholar
• Windschall D, Horneff G. Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis. Clin Rheumatol. 2016;35(12):2925–31.
   PubMed Web of Science ®Google Scholar
• Tzaribachev N, Kuemmerle-Deschner J, Eichner M, Horneff G. Safety efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 4 years. Rheumatol Int. 2008;28(10):1031–4.
   PubMed Web of Science ®Google Scholar
• Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009;60(9):2794–804.
   PubMed Web of Science ®Google Scholar
• Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011;63(7):929–36.
   PubMed Web of Science ®Google Scholar
• Consolaro A, Bracciolini G, Ruperto N, Pistorio A, Magni-Manzoni S, Malattia C, et al. Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheum. 2012;64(7):2366–74.
   PubMed Web of Science ®Google Scholar